The GOP senator objected to Secretary Kennedy's recasting of the influential advisory panel, which has sparked criticism from ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...

The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

Jaqueline Corrigan-Curay, who serves as acting head of the FDA’s Center for Drug Evaluation and Research, will depart next ...

Illumina expects that adding SomaLogic will aid its “multiomics” business strategy and strengthen the value of its gene ...

Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly extended survival, which will be necessary to support an FDA submission.

A dramatic pullback in public biotech investment catalyzed by economic and regulatory upheaval is putting even more stress on ...